Of other interest in the commentary from the panel of expert practitioners was that both potential gene cell and stem cell therapy required technically difficult surgery. It would require surgical training of the specialist in these procedures and was associated with increased risk of retinal detachment in patients. In addition patients required steroid or immuno-suppressive therapy respectively and as a result of all this it was not likely to be taken up readily by what I would call general practice specialists.
Ann: Opthea Reports Positive Data from Ph1b DME Study of OPT-302, page-8
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
78.0¢ |
Change
-0.010(1.27%) |
Mkt cap ! $960.2M | |||
| Open | High | Low | Value | Volume |
| 79.0¢ | 79.5¢ | 74.5¢ | $2.420M | 3.109M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 77.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 78.0¢ | 77447 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |